U25. NMR: Biomedical Applications I
- Scientific Director: Prof. Carles Arús Carles.Arus@uab.es
- Scientific Coordinator: Ana Paula Candiota AnaPaula.Candiota@uab.cat
- Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
- Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
- Phone: +34 935 814 126
- Web: GABRMN-UAB seRMN-UAB
The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) (http://sermn.uab.cat/) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB . This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN) (http://gabrmn.uab.es/), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.
The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.
The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.
The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.
- U25-S01. NMR spectrometer 250MHz robot/250MHz auto/360MHz/400MHZ (Onsite&Remote) OUTSTANDING
- U25-S02. NMR spectrometer 500MHz/600MHz (Onsite&Remote) OUTSTANDING
- U25-S03. NMR spectrometer 400 MHz with HRMAS/CPMAS probes (Onsite&Remote) OUTSTANDING
- U25-S04. 500 MHz spectrometer HPLC-NMR(Onsite&Remote) OUTSTANDING
- U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
- U25-S06. Dynamic nuclear polarizer HyperSense® (Onsite&Remote) OUTSTANDING
- U25-S07. Focused Microwave Fixation system (Onsite&Remote) OUTSTANDING
- U25-S08. NMR consultancy for processing and interpreting data (Onsite&Remote)
- U25-S09. Access to specific software and database (Remote) OUTSTANDING
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
- U25-E01. Two AVANCE 250 MH z
- U25-E02. An AVANCE 360 MH z
- U25-E03. AVII 400 MH z
- U25-E04. AVIII 400 MH z
- U25-E05. AVANCE 500 MH z
- U25-E06. AVIII 600 MH z
- U25-E07. BioSpec 70/30 300 MH z
- U25-E08. Focused Microwave Fixation System
- U25-E09. Hypersense sample polarizer
In addition to the indicated equipment, it has:
- U25-E10. Animal housing
- U25-E11. Software packages
- AMIX software page (http://www.bruker-biospin.com/amix.html): analysis of mixtures, metabolomic studies, etc.
- INTERPRET decision-support system for human brain tumour diagnosis (based on MRS and SpectraClassifier)
- Databases of human brain tumour data.
Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I. is givin a talk about “Nosological images of response to therapy based on metabolomic information by magnetic resonance: a step beyond the standard image” next June 6, on Barcelona. According to Dr. Candiota, “The reliable characterization of the treatment response in glioblastoma (GB) is a key factor in improving the survival and prognosis of patients. Image (MRI) and spectroscopic image (MRSI) by magnetic resonance respectively provide morphological and metabolotic profiles of GB, but in general they are not as robust to produce surrogate biomarkers in response to short-term[...]
Silvia Lope-Piedrafita and Nuria Arias Ramos, Scientists of NANBIOSIS U25 NMR: Biomedical Applications I, have participated as co-authors in chapters of the book “Preclinical MRI – Methods and Protocols“. Editors: María Luisa García Martín y Pilar López Larrubia. This book, also co-authored by other researchers of CIBER-BBN, as Guadalupe Soria y Raul Tudela, is organized into 7 parts : -Part 1 covers the basics of MRI physics, relaxation, image contrast, and main acquisition sequences; -Part 2 describes methodologies for diffusion, perfusion, and functional imaging; -Part 3 looks at in vivo spectroscopy; -Part 4 explores special MRI techniques that are less known in the field; -Parts 5 and[...]
Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I, is now part of the Panel of experts from the Autonomous University of Barcelona. This panel aims to offer their knowledge and experience to the media in case they have questions on specific issues.[...]
Last 13 and 14 of November, CIBER-BBN has celebrated its 11th Annual Conference in Hotel Santemar in Santander. In this conference there was a poster session with the participation of the following Units of NANBIOSIS. Special mention deserves Unit 1 with Neus Ferrer as Director and Paolo Saccardo as Coordinator (in the picture): Posters: U1. Protein Production Platform (PPP): Engineering protein complexes as nano- or micro-structured vehicles or drugs for human and veterinary medicine. Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, José Vicente Carratalá, Olivia Cano-Garrido, Mercedes Márquez, Paolo Saccardo, Rosa Mendoza, Raquel Díaz, Héctor, López-Laguna, Julieta Sánchez, Anna Obando, Amanda Muñoz, Andrés Cisneros, Eric Voltà, Aida Carreño, José[...]
Ana Paula Candiota and Carles Arús, Scientific Coordinator and Scientific Director of Unit 25 of NANBIOSIS, jointly with other GABRMN members, have recently published an interesting article in the journal Pharmaceuticals, (Special Issue An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2). This article is also co-authored by scientifics of a research group with renowned prestige in CK2 research field, the Protein Phosphorylation group, del Dipartimento di scienze biomediche (Università degli Studi di Padova). This publication describes a study with the preclinical glioblastoma (GB) model and its treatment, centered in exploring the potential of[...]
MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM
Nuria Arias Ramos from GABRMN-UAB, research group coordinator of Unit 25 of NANBIOSIS, presented on January 30th, an oral communication at the youngSMIN | young Spanish Molecular Imaging Network Meeting. The title of the communication is “Multi slice MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM”, written by Nuria Arias-Ramos, SilviaLope-Piedrafita, Victor Mocioiu, Margarida Julià-Sapé, Carles Arús and Ana Paula Candiota. The work is basically centered in extending the preliminary GABRMN study based on MRSI acquired in a preclinical glioblastoma (GB), both under treatment and control, with pattern recognition and source extraction for noninvasive therapy[...]
Last November took place in CosmoCaixa, Barcelona, the B-Debate Days Imaging for Life. Molecules from Diagnostics and Therapy. The event, organized by B·Debate (an initiative of Biocat and “la Caixa” Foundation), IBB and LJS, was focussed on Biomolecular Imaging, with emphasis on molecular, cellular, tissular and small animal research, as well as biomedical applications, including noninvasive diagnostics, image guided surgery, multimodal imaging and theranostics. Scientists of NANBIOIS Unit 20 and 25 were invited to participate as guest lecturers: -Simó Schwartz, Scientific Director of Unit 20: New bioluminescent models to target cancer stem cells with nanomedicine. -Ana Paula Candiota, Scientific Coordinator of[...]